Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays

Anna Pavlova; Daniel Delev; Behnaz Pezeshkpoor; Jens Müller; Johannes Oldenburg

doi:10.1160/TH13-08-0690

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 111(05): 851-861
DOI: 10.1160/TH13-08-0690

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays

Anna Pavlova

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany

,

Daniel Delev

²Clinic and Policlinic for Neurosurgery, University Clinic Bonn, Bonn, Germany

,

Behnaz Pezeshkpoor

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany

,

Jens Müller

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany

,

Johannes Oldenburg

¹Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany

› Author Affiliations

Abstract

Summary

About one-third of patients with non-severe haemophilia A (HA) show a discrepancy of factor (F)VIII activity (FVIII:C) measured by one-stage (FVIII:C_1st), two-stage assays or the chromogenic method (FVIII:C_chr). The aim of the study was to characterise the mutation profile in patients with FVIII:C assay discrepancies. FVIII:C discrepancy was considered significant if the calculated ratio between FVIII:C_1st and FVIII:C_chr was ≤ 0.6. In 16 patients FVIII:C_1st was higher than FVIII:C_chr. The reverse phenomenon was observed in 83 patients. Genetic analysis revealed 23 different missense mutations of which 17 were novel. Most mutations, exhibiting a higher FVIII:C_1st were localised in the A1-A2-A3 interface. The majority of mutations associated with FVIII:C_chr>FVIII:C_1st discrepancy were located close to or within the thrombin cleavage sites, FIX or vWF binding sites. Our data show a correlation between FVIII:C and thrombin generation testing with a clear differentiation between patients with haemophilia and normal controls. However, in the subgroup of FVIII:C_1st>FVIII:C_chr discrepancy, the endogenous thrombin potential and peak thrombin parameters were similar to non-discrepant haemophilia patients, while in the inverse discrepancy FVIII:C_chr>FVIII:C_1st, these variables showed values close to that of the normal control group. Certain hereditary F8 mis-sense mutations cause discrepancy in FVIII:C as measured with different assays. This can lead to failure in diagnosing HA or incorrectly classifying the severity of the disease. Therefore, we recommend that initial diagnosis of non-severe HA phenotypes should be based on results of both FVIII:C_1st and FVIII:C_chr assays.

Keywords

Haemophilia A - discrepant assay - missense mutations

Full Text

References

References
1 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-647.
2 Biggs R, Eveling J, Richards G. The assay of antihaemophilic-globulin activity. Br J Haematol 1955; 01: 20-34.
3 Seghatchian MJ, Miller-Andersson M. A colorimetric evaluation on factor VIII:C potency. Med Lab Sci 1978; 35: 347-354.
4 Hathaway WE, Christian MJ, Jacobsen LJ. Variant mild hemophilia Discrepancy in one stage and two stage factor VIII assays. Thromb Haemost. 1983 50. Abstract 357.
5 Parquet-Gernez A, Mazurier C, Goudemand M. Functional and immunological assays of FVIII in 133 haemophiliacs - characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost 1988; 59: 202-206.
6 Duncan EM, Duncan BM, Tunbridge LJ. et al. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-848.
7 Rudzki Z, Duncan EM, Casey GJ. et al. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-406.
8 Keeling DM, Sukhu K, Kemball-Cook G. et al. Diagnostic importance of the two stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954 Leu in theFactor VIIIA3domain. Br J Haematol 1999; 105: 1123-1126.
9 Schwaab R, Oldenburg J, Kemball-Cook G. et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000; 109: 523-528.
10 Nesbitt IM, Hinks JL, Sampson B. et al. Discrepant one two stage FVIIIassays are very common in mild haemophilia A: correlation with FVIIIgene mutations. Thromb Haemost. 2001 Suppl: Abstract OC195.
11 Mumford AD, Laffan M, O_Donnell J. et al. A Tyr346 fi Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002; 118: 589-594.
12 Goodeve A, Hinks J, Nesbitt I. et al. Unusual discrepant factor VIII:C assays in haemophilia A patients with Tyr346Cys and Glu321Lys FVIII gene mutations. Thromb Haemost. 2001 Suppl: Abstract P1370.
13 Roelse J, Mertens K, van Mourik J. et al. Altered sensitivity towards factor IXa explains assays discrepancy in plasma of haemophilia A patients with GLU720LYS substitution in factor VIII. Thromb Haemost. 1999 82. Abstract 5.
14 Gilmore R, Harmon S, Gannon C. et al. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia 2010; 16: 671-674.
15 Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC. et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-480.
16 Trossaërt M, Boisseau P, Quemener A. et al. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost 2011; 09: 524-530.
17 Bowyer AE, van Veen JJ, Goodeve A. et al. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica. 2013 Epub ahead of print.
18 Schwaab R, Oldenburg J, Lalloz MR. et al. Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Hum Genet 1997; 101: 323-332.
19 White II GC, Rosendaal F, Aledort LM. et al. Definitions in hemophilia: recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
20 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
21 Pavlova A, Brondke H, Müsebeck J. et al. Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 2009; 07: 976-982.
22 Ngo JC, Huang M, Roth DA. et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
23 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
24 Goodeve AC, Peake IR. The molecular basic of hemophilia A: genotype-pheno-type relationships and inhibitor development. Semin Thromb Haemost 2003; 29: 23-30. [pic]
25 Poulsen AL, Pedersen LH, Hvas AM. et al. Assay discrepancy in mild aemophi-lia A: entire population study in a National Haemophilia Centre. Haemophilia 2009; 15: 285-289.
26 Pipe SW, Eickhorst AN, McKinley SH. et al. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for non-proteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-183.
27 Pipe SW, Saenko EL, Eickhorst AN. et al. Haemophilia A mutations associated with 1-stage/ 2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685-691.
28 Hakeos WH, Miao H, Sirachainan N. et al. Hemophilia A mutations within the factor VIII A2-A3 subunit destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb Haemost 2002; 88: 781-787.
29 Mazurier C, Gaucher C, Jorieux S. et al. Mutations in the FVIII gene in seven families with mild haemophilia. Br J Haematol 1997; 96: 426-427.
30 Celie PH, Van Stempvoort G, Jorieux S. et al. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol 1999; 106: 792-800.
31 Lyall H, Hill M, Westby J. et al. Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?. Haemophilia 2008; 14: 78-80.
32 Cid AR, Calabuig M, Cortina V. et al. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008; 14: 1049-1054.
33 Chantarangkul V, Clerici M, Bressi C. et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003; 88: 547-554.
34 Beltran-Miranda CP, Khan A, Jaloma-Cruz AR. et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-334.
35 Siegemund T, Petros S, Siegemund A. et al. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90: 781-786.
36 Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 02: 1954-1959.
37 Gerotziafas GT, Depasse F, Busson J. et al. Towards a standardization of throm-bin generation assessment: the influence of tissue factor, platelets and phos-pholipids concentration on the normal values of Thrombogram-Thrombino-scope assay. Thromb J 2005; 03: 16-20.
38 Castroldi E, Rosing J. Thrombin generation test. Thromb Res 2011; 127 (Suppl. 03) S21-25.
39 Haidl H, Cimenti C, Leschnik B. et al. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006; 95: 772-775.
40 Fritsch P, Kleber M, Rosenkranz A. et al. Haemostatic alterations in overweight children: Associations between metabolic syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis 2010; 212: 650-655.